# Aptatek Biosciences

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/aptatek-biosciences

- Industry: Medical Devices & Equipment
- Headquarters: Princeton, US
- Website: www.aptatek.com
- Total disclosed funding: $4M
- Latest round: Seed (Mar 16, 2022)
- Investors on record: 3

## About

Based in New Jersey, US, and founded in 2015 by Milan Stojanovic, and Tilla Worgall, Aptatek Biosciences, Inc. develops portable disease management devices to improve wellness, compliance, and life quality of chronic disease patients. In June 2024, returning investors Canterbury Scientific Ltd and National PKU Alliance co-led an undisclosed amount of venture funding for Aptatek Biosciences, Inc. As of March 2022, Michael Boyce-Jacino is the CEO of Aptatek Biosciences, Inc.

Aptatek Biosciences provides portable disease management devices that offer clinical-grade testing for people affected by phenylketonuria (PKU). The company also provides Aptatek platform, an in-home solution that helps transform the disease management of patients.

The company plans to use its proceeds from June 2024 funding to support the completion of its clinical studies.

## Funding rounds

- Seed, Mar 16, 2022, $4M — Longview Innovation, Canterbury Scientific Ltd, National PKU Alliance

## Investors

- Longview Innovation (https://capitalatlas.ai/funds/longview-innovation) — Seed
- Canterbury Scientific Ltd — Seed
- National PKU Alliance — Seed